Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The market doesn't always make sense.
Quite honestly, it doesn't matter who it is, or why.
The charts don't lie.
BIOF Shares Appear to be Under Accumulation
https://altitradepartners.blogspot.com/2021/11/these-three-biof-charts-seem-to-show.html
Yes, it appears that the 10/25/21 update is the latest and greatest version of their corporate presentation.
This pitch deck is filled with a lot of great information.
Every BIOF investor, and potential investor, should go through this presentation thoroughly and completely.
It looks like you have found one of the hidden gems buried within ;>)
https://ipo.llnl.gov/technologies/energy-and-environment/inexpensive-environmentally-friendly-and-highly-permeable
Updated presentation now on company website.
https://www.bluebiofuels.com/wp-content/uploads/2021/10/BIOF-Company-Presentation-10-25-21-3.pdf
While your points are certainly valid, we doubt that Nostrum would have put additional monies into CRXM without having a serious commitment, and a plan, to move the Generx trials forward.
Subsequent to the current period ending September 30, 2020, between the period May 31, 2021 through September 30, 2021, Nostrum provided an additional $300,500 in equity capital to support the operations of the Company. In exchange for the equity financing, the Company plans to issue Nostrum shares of the Company’s Series B Preferred Stock which converts into the Company’s common stock at a conversion rate of $0.0113 per share. At this point, the Company’s cash resources are insufficient to (1) support the Company’s ongoing working capital requirements, financial obligations and outstanding agreements and (2) advance the cGMP manufacture of Generx [Ad5FGF-4], pursuant to a manufacturing agreement with Texas-based FujiFilm Diosynth Biotechnologies, as needed to initiate the previously announced Phase 3 AFFRIM clinical study.
https://www.otcmarkets.com/filing/html?id=15304046&guid=eRtwknSGDNG9dth
We couldn't agree more. The shares are definitely under accumulation, and there has to be a good reason for someone to do that.
The large drop in price awhile ago was met with strong buying, which took the shares right back up to their previous trading range.
We continue to follow this trading pattern very closely.
It's just a matter of time.
https://altitradepartners.blogspot.com/2021/11/blue-biofuels-returns-to-its-former.html
https://altitradepartners.blogspot.com/2021/10/what-could-these-two-charts-be.html
https://altitradepartners.blogspot.com/2021/09/blue-biofuels-erases-oversold-condition.html
https://altitradepartners.blogspot.com/2021/09/blue-biofuels-get-torched-by-investors.html
Docj,
We certainly can understand your pain, but it would be a breach of fiduciary duty if CRXM management were to offer select shareholders some sort of bonus of additional shares, while not doing so for the rest of the same class of equity holders.
All shareholders need to be treated the same way, without favor or discrimination, irrespective of how long they have held their shares.
To do otherwise, is contrary to the just and equitable treatment of the entire class of common stakeholders, as the owners of the company.
Docj,
I have been aware of this company since the early 2000's, when Chris Reinhard and I were working on trying to save another micro-cap company, named Ontro (later re-named OnTech), located in San Diego.
I decided not to invest in CRXM until recently, since I feel that the risk/reward ratio is now very favorable.
In another 3-5 years, this will be a very different company with a totally different valuation.
CHECK THIS OUT !!!!!
CHECK THIS OUT !!!!!
CHECK THIS OUT !!!!!
CHECK THIS OUT !!!!!
We found this a few minutes ago
Not much follow through today.
All of a sudden Conservative media properties have become HOT !!!
https://seekingalpha.com/symbol/CBMJ
All of a sudden Conservative media properties have become HOT !!!
https://seekingalpha.com/symbol/CBMJ
Fretting over all of this is a waste of time and energy.
We won't spend any more time on it.
It will get done, when it gets done.
When it does, we will return to the CRXM board with our thoughts.
We are signing off for now.
As was stated in the letter from CEO Chris Reinhard, which you posted on 9/25/21, CRXM's attorneys informed them that as long as they had a balance sheet not older than 16-months, that they would "technically" be considered current in their filing requirements.
"Importantly, with respect to financial information, the requirement is that the broker has access to a balance sheet that is not older than 16 months before the submission of the quotation, and a statement of operations for the 12 months preceding the balance sheet. See 15c2-11(b)(5)(i)(L). Legal counsel has advised us that the recent filing of our Gene Biotherapeutics’ Quarterly Report on Form 10-Q for the period ended June 30, 2020 establishes Gene Bio’s compliance with the Rule, and that we would expect broker dealers to continue to post the bid and ask for CRXM until October 31, 2021."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166080983
This appears to be born out by the information which we posted yesterday from our securities attorney, Laura Anthony.
"A Company that follows the Alternative Reporting Standard must have posted audited financials dated within 16 months at all times in order to maintain compliance with Rule 15c2-11."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166424454
We would expect to see at least one additional filing, for the period ending 9/30/20, before the end of this month.
We actually take comfort in the fact that BIOF management refrains from putting out a bunch of fluff press releases.
So many other OTC companies and penny stocks do this, hoping to somehow "manage the stock price".
These guys are managing the company, knowing that the stock price will eventually reflect the value of the CTS 2.0 technology.
They know what they have, and what it is worth.
Once the market figures this out, and they release information for the world to see, this stock should attract a lot of new investors bidding against each other for position.
In the meantime, we wait patiently for that day to come.
Schwab is not allowing clients to trade CRXM either.
To the best of our knowledge, no broker/dealer is allowing trades since there is not a current bid to sell into.
The best way to look at this right now is as if CXRM is a private company with no public market for the stock.
The good news is that the shares have intrinsic value. The bad news is that shareholders cannot realize what value it does have, since the public market has temporarily gone away.
Give it time. Things will eventually change soon.